MedTrace Logo

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00866697 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 940

Last updated 2021-02-16

Study results available
· View outcomes & findings →

Summary

This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.

Conditions

Interventions

DRUG

Pazopanib

Pazopanib 800 mg tablet daily for 104 weeks (24 months)

DRUG

Placebo

Matching placebo 800 mg tablet daily, for 104 weeks (24 months).

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-26
Primary Completion
2012-07-08
Completion
2017-08-24
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • China
  • Denmark
  • France
  • Germany
  • Hong Kong
  • Ireland
  • Italy
  • Japan
  • Norway
  • South Korea
  • Spain
  • Sweden
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866697 on ClinicalTrials.gov